prikaz prve stranice dokumenta Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
  Preuzmi
PDF 490.9 KB
Znanstveni rad - Pregledni rad
Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
Clinical Obesity, (2021), 1; 12439. https://doi.org/10.1111/cob.12439
Belančić, Andrej; Kresović, Andrea; Troskot Dijan, Marija

Povezani objekti
COVID-19 | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Belančić, A., Kresović, A. i Troskot Dijan, M. (2021). Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity, (1), 6. doi: 10.1111/cob.12439

Belančić, Andrej, et al. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity, br. 1, 2021, str. 6. https://doi.org/10.1111/cob.12439

Belančić, Andrej, Andrea Kresović i Marija Troskot Dijan. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity br. 1 (2021): 6. https://doi.org/10.1111/cob.12439

Belančić, A., Kresović, A. i Troskot Dijan, M. (2021) 'Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?', Clinical Obesity, (1), str. 6. doi: 10.1111/cob.12439

Belančić A, Kresović A, Troskot Dijan M. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity [Internet]. 10.01.2021. [pristupljeno 13.07.2024.];(1):6. doi: 10.1111/cob.12439

A. Belančić, A. Kresović i M. Troskot Dijan, "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?", Clinical Obesity, br. 1, str. 6, Siječanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:347912. [Citirano: 13.07.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:347912
Podaci o radu
Naslov (engleski)Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
AutorAndrej Belančić
AutorAndrea Kresović
AutorMarija Troskot Dijan
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
The aim of the present manuscript is to discuss on potential pros and cons of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as glucose‐lowering agents during COVID‐19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without diabetes mellitus type 2. Besides being important glucose‐lowering agents, GLP‐1RAs pose promising anti‐inflammatory and anti‐obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP‐1RAs seem to be potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose‐lowering) agents during COVID‐19 pandemic times.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaClinical Obesity
Brojčani podacibr. 1, str. 6, 12439
p-ISSN1758-8103
e-ISSN1758-8111
DOIhttps://doi.org/10.1111/cob.12439
URN:NBNurn:nbn:hr:184:347912
Datum objave publikacije2021-01-10
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1111/cob.12439
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2021-01-19 21:56:50